Men with prostate cancer are being denied NHS access to a treatment used by Lord Cameron, a senior doctor has revealed.

A new study led by researchers at The University of Texas MD Anderson Cancer Center found that prostate cancer patients with low testosterone levels may have a higher risk of cancer progressing to a ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

Learn the key warning signs of prostate cancer that men often overlook. Early awareness can make all the difference.

The average age of men who get diagnosed is 67.

New study finds microplastics in 90% of prostate cancer tumors, with double the concentration in cancerous tissue compared to healthy tissue from patient samples.

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

J&J JNJ announced that the European Commission has approved its precision therapy, Akeega (niraparib and abiraterone acetate dual action tablet), for expanded use in prostate cancer. The regulatory ...

Thirty-six progressive mCRPC patients received TLX591-Tx across three cohorts (enzalutamide, abiraterone, or docetaxel sequence), and all completed two planned doses without emergent, unexpected ...

News, features, and commentary about cancer-related issues ...

The addition of Zytiga (abiraterone) to Truqap (capivasertib) significantly prolonged radiographic progression-free survival ...